[Early recognition of antipsychotic malignant syndrome: prevention from worse in young people with dementia].

Antipsychotic malignant syndrome (AMS) sometimes is difficult to recognize. Four young persons with dementia developing AMS are presented. We emphasize that there may be signs to consider this diagnosis and how to distinguish between serotonergic syndrome and delirium.

Psychotropic drug use in community-dwelling people with young-onset dementia: two-year course and determinants.

Objectives: The aim of this study was to describe the course of psychotropic drug use in people with young-onset dementia and to explore possible associations with age, sex, dementia severity, dementia subtype and neuropsychiatric symptoms.

Methods: Psychotropic drug use was studied in 198 community-dwelling persons participating in the Needs in Young-onset Dementia study. Data about psychotropic drug use were retrieved at baseline, as well as at 6, 12, 18 and 24 months and was classified into five groups (antiepileptics, antipsychotics, anxiolytics, hypnotics/sedatives and antidepressants) and quantified as 'present' or 'absent'.

Survival and life-expectancy in a young-onset dementia cohort with six years of follow-up: the NeedYD-study.

Objectives: The aim of this study was to investigate survival time and life-expectancy in people with young-onset dementia (YOD) and to examine the relationship with age, sex, dementia subtype and comorbidity.

Design, Setting And Participants: Survival was examined in 198 participants in the Needs in Young-onset Dementia study, including participants with Alzheimer's dementia (AD), vascular dementia (VaD) and frontotemporal dementia (FTD).

Measures: The primary outcomes were survival time after symptom onset and after date of diagnosis.

The Progression of Dementia and Cognitive Decline in a Dutch 2-Year Cohort Study of People with Young-Onset Dementia.

Background: The progression of dementia in people with young-onset dementia (YOD) is relatively unknown.

Objective: To investigate the progression of dementia and cognitive decline in the three most common subtypes in YOD and to explore which factors are associated with this course.

Methods: The course of dementia was examined in 198 people with YOD.

Prevalence of Comorbidity in Patients With Young-Onset Alzheimer Disease Compared With Late-Onset: A Comparative Cohort Study.

Objectives: With the lack of a cure for Alzheimer disease (AD), the identification of comorbidity is important to reduce the possibility of excess disability. Although comorbidity in patients with late-onset AD (LO-AD) is common, for people with young-onset AD (YO-AD), it is unclear how often comorbidity occurs. Furthermore, it is uncertain whether comorbidity in patients with YO-AD differs from that in patients with LO-AD.